4.7 Review

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

期刊

PHARMACEUTICS
卷 13, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics13020200

关键词

CTCL; topical formulation; bexarotene; targeted therapy; interferon; HDAC inhibitors

资金

  1. Japan Agency for Medical Research and Development [18lm0203062h0001]

向作者/读者索取更多资源

This review evaluates the available therapeutic options for early- and advanced-stage CTCL in clinical practice, as well as the ongoing clinical trials for novel regimens in the treatment of CTCL.
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据